drugset / Trial / NCT04624867

Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch

NCT04624867

Phase 1 Unknown 240 enrolled Noven Pharmaceuticals, Inc.
NaSingle-groupOpen-labelOther

Summary

A randomized, evaluator-blinded study to assess skin irritation and skin sensitization of HP-1050 transdermal system (HP-1050) in comparison to XULANE patch in healthy female volunteers.

Timeline

Start
2020-11-03
Primary completion
2022-01-31
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HP-1050 Unknown Other
Subject Transdermal Contraceptive Unknown Other

Indications

No indication recorded.